Perrigo PPA Product Withdrawal Costs Could Reach $19 Mil.
This article was originally published in The Tan Sheet
Executive Summary
FDA's request that drug companies voluntarily withdraw phenylpropanolamine-containing cough/cold remedies and appetite suppressants from the market is expected to have no significant, long-term financial impact on two major private labelers who are now reformulating products.